… SGT-53 Antibody fragment to transferrin receptor Plasmid DNA with p53 gene Phase II
clinical trial A complex of cationic liposome encapsulating p53 DNA sequence in a plasmid …

… Aminosilane-functionalized ordered silica materials (SBA-15) … Hollow mesoporous silica
nanoparticles have extraordinary … Nanosized silica particles and silica-modified nanoparticles …

… encapsulation in an MNMP carrier offers an increased number … Moreover, the combination
of the drug carrier and contrast … Batch-to-batch variation is mainly affected by modifications of …

… Other strategies including surface-modification of the microscale and nanoscale drug
carriers [57, 58], using specific organic structures (as linkers) [59, 60], can provide irradiation-…

… The release of the drug (doxorubicin) from the carrier at 37C … silica nanoparticle system with
3-nm pores and loaded it with … Modification of the nanoparticle surface by the deposition of …

… Selfamplifying RNA (can also be delivered as a plasmid DNA… host are genetically modified
ex-vivo with lentiviral vectors and … of plasmid DNA into the nucleus of post-mitotic primary cells …

… modification of ligands to obtain hierarchical targeting capabilities [Citation61]; ii) reducing
the size of drug/carrier … SiNN was functionalized with short amino silanes that have positively …

… developed as a universal carrier for multiple targeting agents … with Tz-modified mesoporous
silica nanoparticles (MSNs-Tz) (… capture capacity, the aminosilane technique exhibited the …

… be induced by aminosilane coated iron oxide NPs [127, 128]. … NMs in the form of plasmid
DNA, proteins, and virus particles … polyamidoamine dendrimer modified with guanidinobenzoic …

… and their low tunability for surface modification [59,60]. … HNF3 plasmid DNA (pDNA) was
efficiently transported by … , emulsions, and nanoparticles are colloidal drug carriers that are used …